Market closed
Sage Therapeutics/$SAGE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sage Therapeutics
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Ticker
$SAGE
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
353
Website
SAGE Metrics
BasicAdvanced
$479M
-
-$6.59
0.94
-
Price and volume
Market cap
$479M
Beta
0.94
52-week high
$14.97
52-week low
$4.62
Average daily volume
1.2M
Financial strength
Current ratio
7.419
Quick ratio
7.224
Long term debt to equity
2.262
Total debt to equity
2.545
Management effectiveness
Return on assets (TTM)
-35.90%
Return on equity (TTM)
-63.37%
Valuation
Price to revenue (TTM)
11.478
Price to book
1.03
Price to tangible book (TTM)
1.03
Price to free cash flow (TTM)
-1.772
Growth
Revenue change (TTM)
-52.30%
Earnings per share change (TTM)
-27.14%
3-year revenue growth (CAGR)
86.99%
3-year earnings per share growth (CAGR)
-5.47%
What the Analysts think about SAGE
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Sage Therapeutics stock.
SAGE Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
SAGE Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
SAGE News
AllArticlesVideos
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Stockholders to Inquire about Securities Investigation
Accesswire·1 day ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Investors to Learn More About the Investigation
Accesswire·3 days ago
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Accesswire·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Sage Therapeutics stock?
Sage Therapeutics (SAGE) has a market cap of $479M as of April 26, 2025.
What is the P/E ratio for Sage Therapeutics stock?
The price to earnings (P/E) ratio for Sage Therapeutics (SAGE) stock is 0 as of April 26, 2025.
Does Sage Therapeutics stock pay dividends?
No, Sage Therapeutics (SAGE) stock does not pay dividends to its shareholders as of April 26, 2025.
When is the next Sage Therapeutics dividend payment date?
Sage Therapeutics (SAGE) stock does not pay dividends to its shareholders.
What is the beta indicator for Sage Therapeutics?
Sage Therapeutics (SAGE) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.